Clinical Efficacy of Modified Shaofu Zhuyutang Combined with Zhengs Rebuzhen Therapy on Pain Caused by Adenomyosis / 中国实验方剂学杂志

ABSTRACT

Objective:To observe the effect of modified Shaofu Zhuyutang combined with Zheng's Rebuzhen therapy on pain caused by adenomyosis (cold coagulation and blood stasis syndrome) and levels of vascular endothelial growth factor (VEGF), matrix metalloproteinases-9 (MMP-9), tissue inhibitors of matrix metalloproteinases (TIMP-1) and prostaglandin. Method:One hundred and twenty-eight patients were randomly divided into control group (63 cases) and observation group (65 cases) by random number table. Patients in control group got desogestrel and ethinylestradiol tablets since the first day of menstruation for consecutive 21 days, 1 granule/time, 1 time/day, and Zheng's Rebuzhen therapy for consecutive 10 days during the menstruation, 1 time/day. In addition to the therapy of control group, patients in observation group were also given Shaofu Zhuyutang, 1 dose/day. A course of treatment was 3 menstrual cycles. Before and after treatment, cox menstrual symptom scale (CMSS) of COX, visual simulation of dysmenorrheal (VAS), chronic pelvic pain, pictorial blood loss assessment chart (PBAC) and cold coagulation and blood stasis syndrome were scored. And uterine volume and endometrial thickness were evaluated by B-mode ultrasonography. And levels of VEGF, MMP-9, TIMP-1, prostaglandin E2 (PGE2), prostaglandin F2α(PGF2α) and cancer antigen were detected. Result:After treatment, the clinical efficacy in observation group was superior to that in control group (Z=2.445, PPP2α and CA125 were lower than those in control group (P2 were higher than those in control group (PConclusion:In addition to desogestrel and ethinylestradiol tablets combined with Zheng's Rebuzhen therapy, modified Shaofu Zhuyutang can relieve pain and hemorrhage and improve the clinical efficacy. The mechanism may be correlated with the regulation of expression levels of VEGF, MMP-9, TIMP-1 and prostaglandin.